Spike Protein Fragments Promote Alzheimer’s Amyloidogenesis
ACS Applied Materials & Interfaces · 30.08.2023 · 15 (34) · 40317-40329
DOI: 10.1021/acsami.3c09815 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 16.08.2023. Verfasst von Sujian Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nanomedicine Center, The Great Bay Area National Institute for Nanotechnology Innovation, 136 Kaiyuan Avenue, Guangzhou, 510700, China. Hauptthemen laut MEDLINE: Alzheimer Disease, COVID-19, Virus Diseases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Key Research and Development Program of China, Division of Chemical, Bioengineering, Environmental, and Transport Systems.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a major cause of dementia inducing memory loss, cognitive decline, and mortality among the aging population. While the amyloid aggregation of peptide Aβ has long been implicated in neurodegeneration in AD, primarily through the production of toxic polymorphic aggregates and reactive oxygen species, viral infection has a less explicit role in the etiology of the brain disease. On the other hand, while the COVID-19 pandemic is known to harm human organs and function, its adverse effects on AD pathobiology and other human conditions remain unclear. Here we first identified the amyloidogenic potential of 1058HGVVFLHVTYV1068, a short fragment of the spike protein of SARS-CoV-2 coronavirus. The peptide fragment was found to be toxic and displayed a high binding propensity for the amyloidogenic segments of Aβ, thereby promoting the aggregation and toxicity of the peptide in vitro and in silico, while retarding the hatching and survival of zebrafish embryos upon exposure. Our study implicated SARS-CoV-2 viral infection as a potential contributor to AD pathogenesis, a little explored area in our quest for understanding and overcoming Long Covid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanomedicine Center, The Great Bay Area National Institute for Nanotechnology Innovation, 136 Kaiyuan Avenue, Guangzhou, 510700, China.
- Department of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, United States.
- College of Environmental Science and Engineering, Tongji University, 1239 Siping Road, Shanghai 200092, China.
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
- School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 510006, China.
ORCID-Profile: Zhiyuan Song, Nicholas Andrikopoulos, Guotao Peng, Feng Ding, Pu Chun Ke
Förderung
- NIGMS NIH HHS
- National Key Research and Development Program of China
- Division of Chemical, Bioengineering, Environmental, and Transport Systems
- National Natural Science Foundation of China
- National Institute of General Medical Sciences
- National Science and Technology Major Project
Zitieren
APA
Cao, S., Song, Z., Rong, J., Andrikopoulos, N., Liang, X., Wang, Y., Peng, G., Ding, F., & Ke, P. C. (2023). Spike Protein Fragments Promote Alzheimer’s Amyloidogenesis. ACS Applied Materials & Interfaces, 15(34), 40317-40329. https://doi.org/10.1021/acsami.3c09815
Vancouver
Cao S, Song Z, Rong J, Andrikopoulos N, Liang X, Wang Y, et al. Spike Protein Fragments Promote Alzheimer’s Amyloidogenesis. ACS Applied Materials & Interfaces. 2023;15(34):40317-40329. doi:10.1021/acsami.3c09815
BibTeX
@article{Cao2023,
author = {Cao, Sujian and Song, Zhiyuan and Rong, Jinyu and Andrikopoulos, Nicholas and Liang, Xiufang and Wang, Yue and Peng, Guotao and Ding, Feng and Ke, Pu Chun},
title = {Spike Protein Fragments Promote Alzheimer’s Amyloidogenesis},
journal = {ACS Applied Materials & Interfaces},
year = {2023},
volume = {15},
number = {34},
pages = {40317--40329},
doi = {10.1021/acsami.3c09815}
}
EUVIMED